TTrialPathMatch Me to Trials
← Back to trials
RecruitingPulmonary Hypertension

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH. Subjects will be asked to attend a baseline visit where the following will be performed: * Measure your vital signs * Undergo a research blood draw, less than 4 tablespoons * Provide a urine pregnancy test (if applicable) * Review demographics, personal history, and medical history * Review current PAH medications * Complete questionnaires on how your PAH affects you * Complete a test of physical performance * Complete a grip strength test * Undergo an echocardiogram (Echo) * Complete a six-minute walk test * Undergo a Chest CT Scan * Undergo a scan of your body composition (DXA scan) * Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months

Sponsor: University of Pennsylvania

You may qualify if…

  • Signed informed consent prior to initiation of any study mandated procedure.
  • Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \[Humbert 2022\]
  • Idiopathic (IPAH)
  • Heritable (HPAH)
  • Drugs or toxins induced
  • Associated (APAH) with one of the following:
  • Connective tissue disease;
  • Human immunodeficiency virus (HIV) infection;

You may not qualify if…

  • Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:
  • FEV1/FVC ≤ 5th percentile; and
  • FEV1 z-score \< 2.5
  • Prior to enrollment, evidence of severe restrictive defect with
  • TLC \< 5th percentile
  • FEV1 z-score \< 4
  • Prior to enrollment, hospitalization (within 1 week) for decompensated right heart failure
  • More than moderate aortic or mitral valve disease

Where it's recruiting

Pennsylvania

Philadelphia

Rhode Island

Providence

Source: ClinicalTrials.gov · NCT07132788 · last updated 2026-08-19